text:
Breast Clinical Trials
- CINJOG 040406: "Effect of DNA Variations on Breast Cancer Risk and Recurrence. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)"
- CINJOG 040803: "Phase I/II Study of Weekly Abraxane and RAD001 in Women with Locally Advanced or Metastatic Breast Cancer. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)"
- SCUSF 0806: "Phase II Placebo-controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin)"
- ECOG 2108: "A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer"
- NSABP B-43: "A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2‑Positive Ductal Carcinoma in Situ Resected by Lumpectomy"
- NSABP B-47: "A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of TC or Four Cycles of AC Followed by Four Cycles of Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Normal Invasive Breast Cancer"
- RTOG 1005: "A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer"
- SWOG S1007: "A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less"
CINJOG 040406: "Effect of DNA Variations on Breast Cancer Risk and Recurrence. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)"
Evaluation in surgical/medical/radiation oncology/radiology clinic, high risk clinic, or survivors clinic with a history of one of the following:
- Previous biopsy-confirmed diagnosis of breast cancer including DCIS and invasive ductal carcinoma OR
- Previous biopsy-confirmed diagnosis of the marker of increased risk of developing breast cancer LCIS or atypical hyperplasia OR
- Previous biopsy-confirmed diagnosis of benign breast conditions (includes fibrocystic changes, fibroadenoma) with no prior diagnosis of breast cancer OR
Individual participating as a healthy volunteer.
- Willing to undergo venipuncture to obtain 20 ml of blood, and submission of a case report form.
- Age > 18 years.
ENROLLMENT TARGET: 10,000 - *Enrollment is 4107 as of 11/2013
CINJOG 040803: "Phase I/II Study of Weekly Abraxane and RAD001 in Women with Locally Advanced or Metastatic Breast Cancer. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)"
- Adult women (≥ 18 years of age) with metastatic or locally recurrent breast cancer, not amenable to treatment by surgery or radiotherapy
- Histological confirmation of breast cancer that is Her2/neu negative
- Patients may not have received prior chemotherapy for metastatic breast cancer. Prior adjuvant chemotherapy is allowed.
- Patients may have received prior systemic endocrine treatment for advanced breast cancer (i.e. metastatic or locally recurrent breast cancer, not amenable to treatment by surgery or radiotherapy).
- Patients must have at least one measurable lesion. Measurable disease documented and defined as by RECIST criteria (see Section 9). Baseline measurements must be obtained within 4 weeks prior to enrollment.
- NOTE: As the only exception regarding the requirement for at least one measurable lesion, patients with bone metastases as the sole site of disease can be included, provided they have at least 2 lytic bone lesions, detected by either X-Ray, CT scan or MRI.
- Prior radiation therapy allowed to < 25% of the bone marrow and patients must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia). Prior radiotherapy must be completed 30 days before study entry. Lesions that have been radiated in the advanced setting cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy.
- Patients must have an ECOG performance status ≤ 2 (Appendix B).
- Patients on antiangiogenic agents are not excluded from this study.
Patients must have normal organ and marrow function as defined below:
- ANC ≥ 1.5 x 109 cells/L,
- Platelets ≥ 100 x 109 cells/L,
- Hb >9 g/dL,
- Serum Bilirubin ≤ 1.5 x ULN,
- Absence of ascites and encephalopathy due to liver disease,
- INR < 1.5 x ULN,
- ALT and AST, ≤ 2.5x ULN (≤ 5x ULN in patients with liver metastases).
- Serum Creatinine ≤ 1.5 mg/Dl,
- Fasting serum cholesterol ≤ 300 mg/dl or 7.75 mmol/L and fasting triglycerides ≤ 2.5 x ULN,
In case one or both of these thresholds are exceeded, the patient can only be included after initiation of statin therapy.
- Estimated life expectancy of at least 3 months.
ENROLLMENT TARGET: 72 - *Enrollment is 26 as of 11/2013
SCUSF 0806: "Phase II Placebo-controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin)"
Lisinopril or carvedilol phosphate may help reduce side effects caused by trastuzumab. It is not yet known whether lisinopril or carvedilol phosphate is more effective than a placebo in reducing side effects caused by trastuzumab.
This phase II trial is studying lisinopril and carvedilol phosphate to see how well they work compared with a placebo in reducing side effects in patients with HER2-positive breast cancer receiving trastuzumab.
This is a multicenter study. Patients are stratified according to chemotherapy comprising an anthracycline (yes vs. no). Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive oral lisinopril once daily.
- Arm II: Patients receive oral carvedilol phosphate extended-release once daily.
- Arm III: Patients receive oral placebo once daily. In all arms, study treatment begins with the first dose of trastuzumab and continues for up to 52 weeks or until the end of trastuzumab therapy.
-Quality of life is assessed using the EORTC QLQ-C30 questionnaire at baseline, at 52 weeks (or at the end of trastuzumab therapy), and at 18 and 24 months (or 6 and 12 months after the completion of trastuzumab).
-After completion of study treatment, patients are followed up at 3, 6, 9, and 12 months.
- Ambulatory, early stage (I or II) breast and prostate cancer survivors who are at least two years out of treatment (excluding hormonal therapy) with no severe co-morbid conditions (e.g., congestive heart failure, myocardial infarction, angina) that require extensive coordination of specialist care are eligible.
- Diagnosis of HER2-positive breast cancer
- Scheduled to receive adjuvant or neoadjuvant trastuzumab therapy
- Anthracycline-containing regimens allowed
- Patients receive trastuzumab with their chemotherapy allowed for eligibility work-up
- Taxanes are allowed
- Trastuzumab therapy may be given with or after primary chemotherapy
- Pertuzumab may be used in conjunction with trastuzumab
- No metastatic disease
- Hormone receptor status not specified
- Menopausal status not specified
- LVEF ≥ 50% by MUGA or ECHO
- Creatinine ≤ 1.2 mg/dL
- Sitting systolic BP > 90 mm Hg
- Pulse ≥ 60 beats/minute
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to swallow capsules
- Adequate renal function for administration of trastuzumab-containing chemotherapy regimen
- No known cardiac history (i.e., heart failure, myocardial infarction, or radiation-induced cardiac dysfunction)
- No known allergy to either ACE inhibitors or β-blockers
- No history of bronchial asthma or related bronchospastic conditions
- No hereditary or idiopathic angioedema
- No history of severe hypersensitivity reactions to drugs or other causes (e.g., bee stings)
- See Disease Characteristics
- No prior trastuzumab or anthracyclines prior to this chemotherapy regimen
- No current treatment with other angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), such as losartan, β-blockers, or digoxin
- Concurrent participation in other investigational studies allowed
- To determine if administration of lisinopril or carvedilol phosphate extended-release (compared to placebo) will reduce the incidence of trastuzumab-induced cardiotoxicity, as measured by LVEF, in women receiving adjuvant or neoadjuvant trastuzumab for HER2-positive breast cancer.
- To determine whether patients randomized to receive lisinopril or carvedilol phosphate extended-release have fewer interruptions in trastuzumab therapy due to cardiomyopathy.
- To determine whether the treatment effect is consistent in anthracycline and nonanthracycline patient cohorts.
- To determine changes in quality of life (QOL) in patients treated with these regimens.
- To determine the long-term effects of lisinopril and/or carvedilol phosphate extended-release on the prevention of cardiomyopathy and their impact on QOL.
- To compare the predictive value of troponin I and BNP in the identification of trastuzumab-induced cardiotoxicity.
National Enrollment to Date: 355/468
ECOG 2108: "A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer"
OUTLINE: This is a multicenter study. Patients are stratified according to hormone receptor and treatment plan (ER+ or PR+, HER2-, endocrine therapy alone vs. ER+ or PR+, and HER2-, chemotherapy and/or endocrine therapy vs. ER- or PR-, and HER2- vs. HER2+), and number of involved organ systems with distant disease (regional nodes in the maxillary, supraclavicular, and internal mammary locations are not considered distant sites) (1 vs. > 1). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive standard palliative therapy, if needed, to address symptoms such as tumor ulceration, pain, bulky adenopathy causing arm symptoms, and other similar situations. Therapy may consist of radiotherapy alone, surgery alone, or a combination of both.
- Arm II: Patients undergo surgery comprising breast-conserving therapy (BCT) or total mastectomy according to patient and treating physician preference. Surgery is to occur no later than 10 weeks after completion of 32 weeks of systemic therapy. Free surgical margins must be achieved with re-excision or mastectomy for patients undergoing BCT. After completion of BCT, patients undergo radiotherapy once a day, 5 days per week. Patients who had mastectomy undergo radiotherapy at the discretion of treating physician.
-Patients may undergo blood and tumor tissue sample collection for circulating tumor cells (CTC) burden and future studies.
-Patients complete the Functional Assessment of Cancer Therapy - Breast Trial Outcome Index (FACT- TOI) and FACT - General (22) and the Breast Cancer Subscale (FACT-B) quality-of-life questionnaires at baseline and periodically during study.
-After completion of study therapy, patients are followed up periodically for 5 years.
- Diagnosis of intact primary (not recurrent) invasive carcinoma of the breast
- Stage IV disease
- Confirmation of the primary tumor should be by needle biopsy (preferred)
- Incisional surgical biopsy allowed as long as there is residual palpable or tumor image in the breast
- Patients must be judged to be candidates for complete resection with free margins followed by radiation therapy (if radiation therapy is indicated)
- For women not undergoing maxillary dissection, sentinel node biopsy should document an maxillary nodal burden of 1-2 involved lymph nodes (i.e., ACOSOG Z-11 criteria may be applied)
- Prior non-invasive (DCIS) cancer allowed provided there has been no recurrence
- Prior ipsilateral invasive cancer allowed if more than 5 years previous
- No synchronous contralateral breast cancer
- Patients should have at least one organ system involved with distant metastatic disease
- If patient has only one metastatic lesion/focus, this must be proven by biopsy and the pathology report confirming the diagnosis of primary breast cancer, as well as the metastatic site, must be available
- Must have available radiologic reports documenting disease status within the past 6 weeks prior to initiating systemic therapy
- CNS metastases allowed provided projected survival > 6 months
- Patients must have completed at least 16 weeks of optimal systemic therapy (appropriate to the tumor biological profile and the patient's age and menopausal status)
- If systemic therapy is discontinued for toxicity, but there is no distant progression and at least 12 weeks of therapy have been delivered, then the patient remains eligible
- Radiation therapy (if indicated) must begin within 12 weeks of final therapeutic surgical procedure (including re-excision for free margins and completion of maxillary dissection)
- Patients may register at any time from the time of diagnosis of stage IV breast cancer (if eligibility criteria met) to the time when a maximum of 30 weeks of induction systemic therapy has been completed
- Patients must be randomized within 16-32 weeks after the start of systemic therapy
- Patients must not have experienced disease progression since the start of systemic therapy, as evidenced by radiographic documentation of disease status before treatment and within 4 weeks +/- 2 weeks prior to randomization, including:
- No new sites of disease
- No enlargement of existing sites by 20% or more in longest diameter
- No symptomatic deterioration
- Patients who require radiotherapy to bone metastases during induction systemic therapy are eligible
- Local disease at the primary site must be asymptomatic
- Hormone receptor status known
- See Disease Characteristics
- Menopausal status not specified
- Patients must have adequate organ function to undergo local therapy 4 weeks +/- 2 weeks prior to randomization per investigator discretion and institutional guidelines
- More than 5 years since other primary cancers that were curatively treated
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use an accepted and effective contraception method
- See Disease Characteristics
- To evaluate whether early local therapy comprising surgery of intact primary disease compared to local palliative therapy only in patients with stage IV breast cancer, whose disease does not progress during initial optimal systemic therapy, will result in prolonged survival.
- To compare the time to uncontrolled chest wall disease between patients treated with these regimens.
- To determine whether there is a difference in health-related quality-of-life (HRQOL) between patients treated with these regimens.
- To determine whether the absolute value of circulating tumor cells (CTC) burden at 6 months following randomization (time +6) will be lower in the palliative therapy arm than in early local therapy arm, and whether this value is inversely related to survival (lower CTC, longer survival).
- To collect tumor and blood specimens for future exploration of the biological interactions between the primary tumor and metastatic lesions and the effect of primary tumor resection.
National Enrollment to Date: 165/368
Please contact CINJ before opening/enrolling patients on this trial
NSABP B-43: "A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2‑Positive Ductal Carcinoma in Situ Resected by Lumpectomy"
- On histologic examination, the tumor must be ductal carcinoma in situ (DCIS). (Patients with mixed DCIS and lobular carcinoma in situ [LCIS] are eligible.)
- The DCIS must be HER2-positive as determined by central testing. Central testing to determine HER2 status: Central testing for determination of HER2 status will be performed at a central reference lab according to the ASCO College of American Pathologists (CAP) guidelines and supervised by K.P. Siziopikou, MD, PhD, Director of Breast Pathology, RUMC. HER2 amplification status for B-43 will be evaluated by IHC using the HercepTest® (Dako, Carpinteria, CA) for all cases; cases with a 1+ or 2+ IHC reading will be reflexed to FISH (PathVysion®, HER2 DNA probe kit, by Vysis, Inc, Downers Grove, IL). A 0 or 3+ IHC reading will be considered final for eligibility. As part of the correlative science in B-43, FISH testing will also be performed for all cases (enrolled patients) at a later date.
- Estrogen and/or progesterone receptor status must be determined prior to randomization. (Patients with DCIS that is hormone receptor positive or negative are eligible.)
- All DCIS must have been resected by lumpectomy.
- The margins of the resected specimen must be histologically free of DCIS. For patients in whom pathologic examination demonstrates DCIS present at the line of resection, re‑excision(s) may be performed to obtain clear margins. (Patients who require mastectomy are not eligible.)
- If maxillary staging is performed, nodal staging must be pN0, pN0(i-), pN0(i+) which is defined as isolated tumor cells ≤ 0.2 mm, regardless of the method of detection, i.e., IHC or H&E, pN0(mol-), or pN0(mol+). NOTE: Axillary staging is not required. (Refer to AJCC Staging Criteria in the Treatment Trial Information section in the Members' Area of the NSABP Web site for TNM nomenclature and staging information.)
- The interval between the last surgery for excision of DCIS (lumpectomy or re-excision of lumpectomy margins) and randomization must be no more than 120 days.
National Enrollment to Date: 1498/2000
Please contact CINJ before opening/enrolling patients on this trial
Please contact CINJ before opening/enrolling patients on this trial
NSABP B-47: "A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of TC or Four Cycles of AC Followed by Four Cycles of Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Normal Invasive Breast Cancer"
OUTLINE: This is a non-randomized, multicenter study. Patients are assigned to 1 of 2 treatment groups according to HER2/neu status (HER2/neu 2+ or 3+ staining [group 1] vs. HER2/neu 0 or 1+ staining [group 2]).
GROUP I: Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and trastuzumab (Herceptin®) IV over 90 minutes on day 1 and then over 30 minutes on days 8, 15, 22, 29, 36, and 43. Patients also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22‑26, 29-33, 36-40, 43-47, and 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
GROUP II: Patients receive paclitaxel and undergo radiotherapy as in group 1.
-After completion of study treatment, patients are followed at 4-5 weeks, every 3 months for 1 year, every 4 months for 1 year, every month for 3 years, and then annually thereafter.
- Histologically or cytologically confirmed primary transitional cell carcinoma (TCC) of the bladder
- Histologic evidence of muscularis propria invasion
- Meets 1 of the following stage criteria:
- Stage T2-4a; NX, N0, or N1; and M0 disease
- Clinical stage T1, grade 3/3 disease AND requires definitive local therapy
- Tumor involvement of the prostatic urethra allowed provided the following criteria are met:
- Tumor was visibly completely resected
- No evidence of stromal invasion of the prostate
- No evidence of distant metastases by chest x-ray or CT scan AND abdominal/pelvic CT scan
- Has undergone transurethral bladder resection (as thorough as is judged safely possible) within the past 3-8 weeks, including bimanual examination with tumor mapping
- Sufficient tumor tissue available for HER2/neu analysis
- Not a candidate for radical cystectomy
- Performance status - Zubrod 0-2
- Absolute neutrophil count >= 1,800/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin >= 8.0 g/dL (transfusion or other intervention allowed)
- Bilirubin < 2.0 mg/dL
- SGOT and SGPT < 2.5 times upper limit of normal
- No hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- Creatinine =< 3.0 mg/dL
- LVEF >= 40% by MUGA scan or echocardiogram
- No unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
- No transmural myocardial infarction within the past 6 months
- Not pregnant or nursing
- No nursing for 6 months after completion of study treatment (for patients receiving trastuzumab [Herceptin®])
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after completion of study treatment
- Able to tolerate systemic chemotherapy and pelvic radiotherapy
- No other invasive malignancy within the past 3 years except nonmelanoma skin cancer
- No history of allergic reaction to study drugs
- No history of inflammatory bowel disease
- No acute bacterial or fungal infection requiring IV antibiotics
- No AIDS
- No other severe active comorbidity
- No prior systemic chemotherapy with anthracyclines or taxanes
- No prior systemic chemotherapy for TCC
- No prior pelvic radiotherapy
I. Determine the acute toxicity of paclitaxel and radiotherapy with or without trastuzumab (Herceptin®) in patients who have undergone prior transurethral bladder resection for muscle-invasive transitional cell carcinoma of the bladder.
- Determine the ability of these patients to complete these regimens.
Determine the efficacy of these regimens, in terms of achieving a complete response of the primary tumor, in these patients.
Determine the 5-year disease-free and overall survival of patients treated with these regimens.
- Determine the value of tumor and/or serum biomarkers as predictors of initial tumor response and recurrence-free survival of patients treated with these regimens.
National Enrollment to Date: 2179/3260
Please contact CINJ before opening/enrolling patients on this trial
RTOG 1005: "A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer"
***The cosmesis subset for patients not receiving chemotherapy has met its accrual and will be closed to further enrollment at close of business on Friday March 8th, 2013. The trial as a whole still remains open to accrual.***
OUTLINE: This is a multicenter study. Patients are stratified according to age (< 50 vs. ≥ 50 years), prior chemotherapy (yes vs. no), estrogen-receptor status (+ vs. -), and histology grade (1-2 vs. 3). Patients are randomized to 1 of 2 treatment arms. Treatment begins within 9 weeks of last surgery or chemotherapy delivery.
- Arm I: Patients undergo standard whole-breast radiotherapy (WBI) comprising intensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) 5 days a week for 3-5 weeks followed by a sequential radiotherapy boost to the lumpectomy area 5 days a week for 1-1½ weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients undergo accelerated hypofractionated WBI comprising IMRT or 3D-CRT with a concurrent boost to the lumpectomy area 5 days a week for 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
-Patients' tissue samples may be collected for future research studies.
-After completion of study therapy, patients are followed up for 1 month, at 6 months, and then yearly.
- Pathologically proven diagnosis of breast cancer resected by lumpectomy and whole-breast irradiation (WBI) with boost without regional nodal irradiation planned
- Must meet one of the following criteria:
- Stage I or II breast cancer AND at least one of the following:
- Age < 50 years
- Positive maxillary nodes
- Lymphovascular space invasion (LVI)
- At least 2 close resection margins (> 0 mm to ≤ 2 mm)
- One close resection margin and extensive in-situ component (EIC)
- Focally positive resection margins
- Non-hormone-sensitive breast cancer (estrogen-receptor negative (ER-) and progesterone-receptor (PR-) negative)
- Grade III histology
- Oncotype recurrence score > 25
- Stage 0 breast cancer with nuclear grade 3 ductal carcinoma in situ (DCIS) and patient age < 50 years
- No DCIS and age > 50 years
- No DCIS and age < 50 years and nuclear grade 1 or 2
- Resected by lumpectomy after neoadjuvant systemic therapy
- If multifocal breast cancer, then it must have been resected through a single lumpectomy incision with negative margins
- Breast-conserving surgery with margins defined as follows:
- Negative margins defined as no tumor at the resected specimen edge
- Close resection margins > 0 mm to ≤ 2 mm as follows:
- One close resection margin and EIC
- Two or more close resection margins
- A focally positive resection margin
- Allowable options for mandatory maxillary staging include:
- Sentinel node biopsy alone (if sentinel node is negative, pN0, pN0[IHC-,+])
- Sentinel node biopsy alone, or followed by maxillary node dissection, for clinically node-negative patients as described below:
- Microscopic sentinel node (SN) positive (pN1mic)
- One or two SNs positive (pN1) without extracapsular extension
- Negative SN biopsy after neoadjuvant chemotherapy
- SN biopsy followed by maxillary dissection with a minimum total of 6 maxillary nodes if any of the following exist:
- > 2 positive SN
- Solitary SN that is positive without other sentinel nodes dissected
- Clinically (by either imaging or examination) T3 disease
- Presence of one or more positive SNs with extracapsular extension, clinically node-positive disease, or LVI in the primary tumor
- Axillary dissection alone (with a minimum of 6 maxillary nodes)
- CT-imaging of the ipsilateral breast within 28 days of study entry for the radiation treatment planning
- Must be able to delineate on CT scan the extent of the target lumpectomy cavity for boost (placement of surgical clips to assist in treatment planning of the boost is strongly recommended)
- No clinical evidence for distant metastases, based upon the following minimum diagnostic workup:
- History/physical examination, including breast exam (inspection and palpation of the breasts) and documentation of weight and Zubrod Performance Status of 0-2 within 28 days prior to study entry
- Bilateral mammogram within 90 days prior to study entry
- Bilateral or right and left mammography within 90 days prior to neoadjuvant chemotherapy, diagnostic biopsy establishing diagnosis, or last surgery (breast or axilla)
- No prior invasive or in-situ carcinoma of the breast (prior LCIS is eligible)
- No American Joint Committee on Cancer (AJCC) pathologic T4, N2 or N3, or M1 breast cancer
- Must not have two or more breast cancers that are not resectable through a single lumpectomy incision
- No invasive breast cancer and low-risk (see low risk features below) for 5-year in-breast recurrence after lumpectomy with negative margins, defined as:
- ≥ 70 years old, T1, N0, ER/PR+
- > 50 years old, T1, N0, grade 1-2 breast cancer, ER/PR+
- No suspicious unresected microcalcification, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign
- No non-epithelial breast malignancies such as sarcoma or lymphoma
- No Paget disease of the nipple
- No male breast cancer
- Breast implants allowed
- ANC ≥ 1,800/mm³
- Platelet count ≥ 75,000/mm³
- Hemoglobin ≥ 8.0 g/dL (transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable)
- Negative serum pregnancy test within 14 days of study entry
- Women of childbearing potential must not be pregnant or nursing and willing to use medically acceptable form of contraception during radiotherapy
- No prior invasive non-breast malignancy (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless disease free for a minimum of 5 years prior to study entry
- No severely active co-morbidity, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
- Transmural myocardial infarction within the past 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
- Acquired Immune-Deficiency Syndrome (AIDS) based upon current CDC definition
- HIV testing is not required for entry into this protocol
- No active systemic lupus, erythematosus, or any history of scleroderma or dermatomyositis with active rash
- Medical, psychiatric, or other condition that would prevent the patient from receiving the protocol therapy or providing informed consent
- See Disease Characteristics
- Study entry must be within 50 days of last breast/maxillary surgery and/or last chemotherapy
- No treatment plan that includes regional-node radiotherapy
- No prior radiotherapy to the breast or prior radiation to the region of the ipsilateral breast that would result in overlap of radiation therapy fields
- No intention to administer concurrent chemotherapy for current breast cancer
- To determine whether an accelerated course of hypofractionated whole-breast irradiation (WBI) including a concomitant boost to the tumor bed in 15 fractions following lumpectomy will prove to be non-inferior in local control to a regimen of standard WBI with a sequential boost following lumpectomy for early-stage breast cancer patients.
- To determine whether breast-related symptoms and cosmesis from accelerated WBI that is hypofractionated (in only 3 weeks) with a concomitant boost is non-inferior to standard WBI with sequential boost.
- To determine whether the risk of late cardiac toxicity in patients with left-sided breast cancer treated with hypofractionation will be non-inferior to conventional fractionated radiation therapy (RT) based upon analysis of radiation dosimetry from CT-based treatment planning and NTCP calculations.
- To determine whether CT-based conformal methods intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT) for WBI are feasible in a multi-institutional setting following lumpectomy in early-stage breast cancer patients and whether dose-volume analyses can be established to assess treatment adequacy and likelihood of toxicity.
- To determine that cosmetic results and breast-related symptoms 3 years after hypofractionated breast radiation with concomitant boost will not be inferior to that obtained 3 years after WBI with sequential boost.
- To determine whether future correlative studies can identify individual gene expressions and biological host factors associated with toxicity and/or local recurrence from standard and hypofractionated WBI.
- If shown to be non-inferior, to then determine if accelerated course of hypofractionated WBI including a concomitant boost to the tumor bed in 15 fractions following lumpectomy will prove to be superior in local control to a regimen of standard WBI with a sequential boost following lumpectomy for early-stage breast cancer patients.
- To determine whether treatment costs for hypofractionated WBI with concomitant boost are not higher than WBI with sequential boost
National Enrollment to Date: 1576/2312
SWOG S1007: "A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less"
OUTLINE: This is a multicenter study. Patients are stratified according to Recurrence Score (0-13 vs. 14-25), menopausal status (pre-menopausal vs. post-menopausal), and type of nodal dissection (maxillary lymph node dissection [with or without sentinel node mapping] vs. sentinel node biopsy without maxillary lymph node dissection). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive a protocol-approved chemotherapy regimen based on the patient and/or physician preference. Patients then receive a protocol-approved adjuvant endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive a protocol-approved endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
-Patients may complete health-related quality-of-life (QOL) questionnaires at baseline and periodically during study. Information on Medicare and/or insurance coverage and on health coverage decisions may also be collected periodically.
-After completion of study therapy, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then yearly for at least 15 years.
- Histologically confirmed invasive breast cancer
- 1-3 node-positive disease (pN1mi, pN1a, pN1b, or pN1c) by sentinel node biopsy or maxillary lymph node dissection
- Positive estrogen receptor (ER) and/or progesterone receptor (PR) status according to American Society of Clinical Research/College of American Pathologists (ASCO/CAP) guidelines
- Considered positive if >= 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal [normal epithelial elements] and external controls
- Negative HER-2 as determined by IHC or non-amplified fluorescence in situ hybridization (FISH) for screening
- If HER2 is 2+ by IHC, FISH must be performed and must not be positive (must be a ratio of =< 2.2)
- If IHC is 0 or 1+ by institutional standards, FISH is not required
- Patients with FISH in the indeterminate range (a ratio of 1.8 to 2.2) allowed provided they are not planning to receive treatment with trastuzumab
- Recurrence Score (RS) by Oncotype DX =< 25
- Submission of tissue (paraffin block from primary tumor, positive and negative lymph node block) from surgery required
- Prior diagnosis of DCIS allowed provided it was treated with mastectomy alone (no therapeutic radiation or endocrine therapy)
- No inflammatory breast cancer or metastatic disease
- Must have had breast-conserving surgery with planned radiotherapy or total mastectomy (with or without planned post mastectomy radiation) with clear margins within the past 28-84 days
- Menopausal status: pre- or post-menopausal
- Zubrod performance status 0-2
- Not pregnant or nursing
- Fertile patients must use an effective non-hormonal contraception method while on treatment and for ≥ 3 months after completion of protocol treatment
- No other prior malignancy except adequately treated basal cell or squamous cell skin cancer; in situ cervical cancer; adequately treated stage 0, I, or II cancer from which the patient is currently in complete remission; or any other cancer from which the patient has been disease-free for the past 5 years
- LVEF ≥ 50% if an anthracycline-based regimen is planned
- Patients randomized to chemotherapy may also co-enroll in Phase III trials that compare chemotherapies
- No prior chemotherapy or endocrine therapy for breast cancer
- No prior preventive tamoxifen or raloxifene
- No prior therapeutic breast radiotherapy
- Not requiring concurrent chronic treatment with systemic steroids or other immunosuppressive agents
- Patients randomized to either arm may also co-enroll in Phase III trials that compare local therapies or compare systemic therapies (not including chemotherapy)
I. To determine the effect of endocrine therapy with versus without chemotherapy in patients with node-positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®.
I. To compare overall survival (OS), distant disease-free survival (DDFS), and local disease-free interval (LDFI) by receipt of chemotherapy or not and its interaction with RS.
II. To compare the toxicity across the treatment arms.
III. To perform other assays or tests (in particular the PAM50 risk of relapse score) as they are developed and validated that measure potential benefit of chemotherapy and compare them to Oncotype DX®.
IV. To determine the impact of management with Oncotype DX® on patient-reported anxiety (co-primary Health-Related Quality of Life [HRQL] outcome) prior to screening, after disclosure of test results, and during the randomized trial.
V. To determine the impact of Oncotype DX® on the initial management cost of node-positive, HR-positive, HER2-negative breast cancer.
VI. To compare patient-reported utilities (e.g., QOL) for those randomized to chemotherapy versus no chemotherapy.
VII. To estimate the cost-effectiveness of management with Oncotype DX® vs. usual care using modeling and DFS information from the trial.
VIII. To determine the role of other assays (e.g., PAM50) as predictors of DFS, DDFS, and LDFI of patients randomized to chemotherapy versus no chemotherapy.
IX. To determine the impact of treatment with chemotherapy versus no chemotherapy on patient-reported fatigue and cognitive concerns (secondary HRQL outcomes).
X. To determine the impact of management with Oncotype DX® on patient-reported decision conflict, perceptions regarding Oncotype DX® testing, and survivor concerns prior to screening, after disclosure of test results, and during the randomized trial (secondary HRQL outcomes).
National Enrollment to Date: 1941/4000


text:
Most of the time, when I look at a movie--whether or not I'm inside the target demo-- I know what I'm looking at, I can understand its language, which tends to be fairly universal. Rarely have I felt more in a world that I do not comprehend, than at Scott Pilgrim vs. the World. But I knew when watching it that I was in the hands of a authoritative filmmaker who knew exactly what he was trying to achieve.
Part of Shaun of the Dead filmmaker Edgar Wright's mission was to connect to young people, which he clearly does. He invents new ways here to communicate teen thinking and feeling, referencing music, comics and video games. (This, the New Yorker critic Richard Brody gets right.) Never have I had more folks younger than I am talk about a movie using terms that sail right over my head.
Scott Pilgrim vs. the World (based on the comics) is certainly not like anything you've ever seen before. Wright mixes the structure of musicals and action films to break up what starts out as a fairly naturalistic relationship comedy with wildly fantastical action fights. While he is still dating a younger and nicer girl, Michael Cera's character has to fight off the evil exes of his cool new girlfriend (Mary Elizabeth Winstead). The movie is crammed with characters, color, music and graphics of the wham! bam! ding dong! variety.
While I respect the wit and originality of the film's visual and aural design and script, some of the sprawling ensemble (Kieran Culkin, Chris Evans, Anna Kendrick, Alison Pill, Brandon Routh and Jason Schwartzman) nail the tone better than others. Cera and Winstead are not entirely engaging; Wright is not playing for romance here. Based on the wildly enthusiastic response at San Diego's Comic-Con, I'm sure that young moviegoers will turn out for this. But the film's scope could be narrow.
Here's Metacritic, where the reviews are trending at 56. UPDATE: One critic in her late thirties gets the movie--and doesn't think critics should review its audience. Both the NYT's Tony Scott and the NY Press's Armond White praise the movie. I'm more with Anthony Lane.
Here's my flip cam interview with Edgar Wright, Part One:
Find more videos like this on AnneCam
Part Two:
Find more videos like this on AnneCam
And the trailer:

subset: commoncrawl


text:
Family Law
Family Law Questions? Ask a Family Lawyer Online.
You probably win this - but its up to the court and as you say, the court is interested in "the best intersts of the child." So, if you feel strongly about this then stick to your guns as the court is most probably going to see it your way.
Al the best,
DISCLAIMER: Answers from Experts on JustAnswer are not substitutes for the advice of an attorney. JustAnswer is a public forum and questions and responses are not private or confidential or protected by the attorney-client privilege. The Expert above is not your attorney, and the response above is not legal advice. You should not read this response to propose specific action or address specific circumstances, but only to give you a sense of general principles of law that might affect the situation you describe. Application of these general principles to particular circumstances must be done by a lawyer who has spoken with you in confidence, learned all relevant information, and explored various options. Before acting on these general principles, you should hire a lawyer licensed to practice law in the jurisdiction to which your question pertains.
The responses above are from individual Experts, not JustAnswer. The site and services are provided "as is". To view the verified credential of an Expert, click on the "Verified" symbol in the Expert's profile. This site is not for emergency questions which should be directed immediately by telephone or in-person to qualified professionals. Please carefully read the Terms of Service (last updated February 8, 2012).


text:
JAN 21, 2013 - Real Simple
A Must Read - Share
Break out of your recipe rut with this month of tasty, no-repeat weeknight meals.
Editor's Picks
Show More
Show Less
Hey you have no friends!!! Get to work and start inviting friends to help build your Comunitee. Click Here to invite friends.
© 2011 Comunitee, Inc.


text:
Thursday media watch [21.02.13 AM]: Sylla backed to make impact
The Sun: Gabby Agbonlahor has told fellow Aston Villa frontman Christian Benteke: You're too good to join Arsenal or Tottenham.
ClubCall: Ashley Westwood has been 'really impressed' with Charles N'Zogbia and says he will be 'a big player' in Aston Villa's survival mission. The France international has endured a difficult time at Villa Park since his £9million transfer from Premier League rivals Wigan in summer 2011.
ClubCall: Gabby Agbonlahor has told Christian Benteke to stay with Aston Villa for now and then join a club 'bigger' than Arsenal or Tottenham. Villa hitman Agbonlahor has been impressed with the form of the 22-year-old Belgium international since his £8million summer arrival from Genk, with 15 Premier League goals already in the bag for Paul Lambert's men.
Mirror: Theo Walcott knows Arsenal need to make amends for a miserable week when Aston Villa visit on Saturday.
Best Of The Rest
Daily Mail: Arsene Wenger will be assured he is the man to revive Arsenal's fortunes at a board meeting with the club's American owner Stan Kroenke on Thursday.
The Sun: Robert Lewandowski could still sign for Manchester United this summer — despite suggestions the striker is set for a switch to Bayern Munich.
BBC Sport: Goals from Kevin-Prince Boateng and Sulley Muntari gave AC Milan victory over Barcelona and a huge chance of making the Champions League last eight.
*The extracts on this page are taken from various newspapers and media outlets. They do not necessarily reflect the views of Aston Villa.
Season Tickets
on sale
Buy our
2015/16 kits


text:
Feb 07, 2014
INDIANAPOLIS – The Butler men's tennis team will host Bradley this weekend at the Butler Bubble. Action is scheduled to begin at 1:00 p.m.
The Bulldogs (3-1) have won three-straight matches with wins over Youngstown State, Dayton and Valparaiso. The team will be matched up against Bradley on Saturday who enters the weekend with a record of 2-2.
Butler defeated Bradley by a narrow 4-3 margin one year ago in mid-February. The Braves won the doubles point last year, but the Bulldogs responded by taking four wins in singles competition.


text:
Bombers Baseball/Softball Camp
Date: Monday, 29 of July of 2013 18h00
City: Dothan
Local: DTS Academy
July 29th - August 16th
Ages: 6-16 Girls and Boys
Monday, Tuesday, Thursday
Price: $50 for the entire Camp
TSHIRT: At the beginning of camp we will take orders for Camp TSHIRTS. $12 child $14 adult.
Please Private Message the Name. Date of Birth and phone # for each athlete attending camp.
Walton Park by Northview High School
Thank you, Coach Gerald


text:
Pretty Little Liars
Which Pretty Little Liars Hunk Got Cozy With a Game of Thrones Star on the Red Carpet?
Pretty Little Liars and Game of Thrones may not seem to have a lot in common (though we would beg to differ), but they do undeniably share one trait — they're both totally addictive! We love both the ABC Family murder mystery and the bloody HBO fantasy, so we're always happy when the two worlds collide.
Plenty of Pretty Little Liars stars have expressed love for epic fantasy and the actors who populate Westeros, but one familiar pretty little face was caught on camera getting a full on embrace from Game of Thrones star Sophie Turner.
So, who's the lucky guy getting up close and personal with the girl who plays Sansa? We'll give you a hint: He hasn't been spotted in Rosewood for quite some time...


text:
Back to Hawaii News index
Posted: Friday, July 19th, 2013 1:37 PM HST
Teenager held in carjacking investigation
By 67AM KPUA News
A 19-year old former Mountain View man is in police custody on suspicion of robbery and unauthorized control of a propelled vehicle following a Wednesday night carjacking at a Hilo shopping complex. Police were sent to the Puainako Avenue parking lot at
Target shortly after 6:30 p.m. where a 24-year old Hilo man said a local male brandishing a weapon threatened him, took the keys to his vehicle and fled in the late model Hyundai sedan.
An island-wide bulletin led to the late night recovery of the vehicle in Pohoiki and the arrest of the suspect, along with a 14-year old female who was released to her parents.
Police are viewing video surveillance footage recovered from Target as part of the investigation. If you have any information about the case or witnessed the carjacking, call Detective Clarence Davies III at 961-2384, Detective Grant Todd at 961-2385 or the police non-emergency number at 935-3311.


text:
Ever since transitioning from a music career with indie band 10,000 Things, Brit actor Sam Riley has carved out a fairly interesting CV which originated with an outstanding debut in Anton Corbijn's acclaimed Ian Curtis biography "Control" that lead to a run of flops that included sci-fier "Franklyn,...Read More »
For smaller independent producers, the problem with your long-atttached star suddenly generating new heat is that they're flooded with new offers; bigger films, more tempting films. As such, it can be hard to keep their interest -- Carey Mulligan, for instance, dropped out of British indie "This Bea...Read More »
Ed Westwick, Brooke Shields, Tamsin Egerton & Bill Nighy Also On Board The American Film Market is underway, and we're expecting a tidal wave of project announcements and casting news in the next few days, as fledgling independent projects try to raise their budgets through pre-sales. We've already...Read More »


text:
Doctorate in Sacred Theology (S.T.D.)
S.T.D. Dissertation
- The doctroal dissertation is a "major original research work" in one of the areas of concentration. It must demonstrate:
- the candidate's erudition, judgment, and knowledge of Catholic doctrine;
- proficiency in positive and speculative theology;
- the ability to articulate and synthesize scientific research in a unique manner that advances theological scholarship and promotes engagement with issues encountered by contemporary Christians.
- Dissertations will be written in English. Exceptions require the approval of the dissertation director and the President of the Pontifical Faculty. The dissertation must be of sufficient length to constitute a truly scientific study, normally 150 to 400 pages. Exceptions must have the approval of the President of the Pontifical Faculty.
- The dissertation must conform to the guidelines of the USML Writers' Manual. Please consult the Pontifical Faculty of Theology Scholar's Manual for details specific to the preparation of a dissertation.
- Once the dissertation is approved by the director, the President in consultation with the director, will appoint a second reader to review and evaluate the dissertation.
- Once both the director and the second reader sign off on the dissertation, the candidate submits the manuscript to the Library Director for approval of formatting as outlined in the USML Writer's Manual. Once the Library Director approves the manuscript, the Library Director will forward an electronic copy of the final manuscript to the Registrar, who will produce five (5) copies, loosely bound. These will be the copies used for the Defense.
- Then a third reader, appointed by the President, will receive and read the entire manuscript.
- The defense date will be not be guaranteed any earlier than two months after the third reader has received the dissertation.
- Time Limits
The doctoral dissertation must be completed within a maximum of five years from the date the dissertation proposal was officially accepted. After five years the degree will no longer be assured.
- Public Defense
The candidate must defend the dissertation by examination before a Doctoral Jury convened by the President and composed of the director and the two readers of the dissertation. The examination will be public, at least ninety minutes in duration.
The Chancellor of the University or his delegate will preside.
The candidate will begin the defense with a twenty minute doctoral lecture on the dissertation. Questions will then be addressed to the candidate by each member of the Doctoral Jury (twenty minutes each), and finally, questions will be permitted ex corona for twenty minutes.
- Final Grade
At the end of the defense, each examiner will give two numerical grades, one grade for the dissertation and one for the defense. Successful completion of the Doctorate requires a minimum average of 86% in each of the two grades (the defense and the dissertation). Graduation with honors will be determined by the average of the two grades (the defense and the dissertation).
A candidate who fails the dissertation defense must consult with the President of the Pontifical Faculty to determine the conditions under which a second defense would be permissible. A second failure would disqualify the candidate from receiving the doctorate.
- Publication
Once the dissertation is successfully defended, the readers have approved any required corrections, and the President has obtained the nihil obstat, the candidate will follow the procedures for publication as outlined in the Pontifical Faculty of Theology Scholar's Manual. The Doctorate is not awarded until all requirements of publication are met and all fees are paid.
- University Convocation
In order to participate in the University Convocation at the end of the academic year, a student must have completed all the requirements or the S.T.D. thirty days before the Convocation.


text:
April 20, 2012 5:43 AM
Julia Gautreaux
When it comes to homophobic bullying, males are the most common instigators but also the most common victims, author C. J. Pascoe told a Tulane audience on Wednesday (April 17). Her book, Dude, You're a Fag: Masculinity and Sexuality in High School, links bullying to society's definitions of masculinity.
Pascoe spoke for the third annual Marla Custard Lecture on Gender and Sexuality hosted by the Newcomb College Center for Research on Women and the Newcomb College Institute.
Her topic was timely. Also on Wednesday, an anti-bullying bill for public schools that was being considered by a Louisiana legislative committee failed to move forward. The bill would have provided a clearer definition of bullying and required schools to train faculty to identify such harassment.
In her lecture, Pascoe delved into what lies at the heart of homophobic bullying.
She said it is linked to a male's attempt to achieve society's definition of masculinity, leading to a compulsion to idolize heterosexuality and deride homosexuality.
Society's narrow definition of masculinity as the ability to impose one's will on others "through power, competence, dominance and inherent heterosexuality" is not only exceptionally degrading, but also highly detrimental to day-to-day interactions, Pascoe said.
Research shows that "90 percent of recent school shootings involved boys who were teased for being gay," she said.
In her book, which won the Book of the Year Award from the American Educational Research Association, Pascoe suggests ways to redefine gender norms that are damaging to both boys and girls.
She is an assistant professor of sociology at Colorado College. Her current research focuses on gender, youth, homophobia, sexuality and new media.
Julia Gautreaux is a sophomore communication major.
Tulane University, New Orleans, LA 70118 504-865-5000 firstname.lastname@example.com


text:
my Nutrition
my Fitness
Other Goals
my SparkPoints
Web Search
Articles & Videos Home
Health & Wellness
Health A-Z
Cold & Flu
GERD (Heartburn)
Healthy Heart
High Blood Pressure
High Cholesterol
Irritable Bowel Syndrome (IBS)
Pain Management
Seasonal Allergies
Weight Loss
Healthy Family
Pregnancy & Postpartum
Instant Inspiration
Lifestyle Centers
Beauty & Style
Brides To-Be
Family Wellness
Healthy Home
Pet Health
Senior Health
The SparkPeople Blog
Community Home
Message Boards
Challenge Central
Secrets of Success
Member Blogs
Friend Feed
Advertisement --
Learn more
about ads on this site.
You look so good!
Tuesday, July 23, 2013
I've been getting that a lot lately from people who know I've been working on losing weight. I can take the compliment sincerely from certain people, like my skinny friends who don't need to lose weight and I know aren't in need of losing anything, but when I get that from some people who could stand to lose a few (or fifty or more) pounds for their frames, I wait for the added part "how did you do it?", but more often than not, it doesn't come.
I know part of it is that I know it can be done with a little discipline, but the other part of me wants to think they're happy with themselves as they are and don't want to change. I have had real discussions with some people who seem to want to change their diets so they can be healthy, no matter if they have only a few or they have many to lose, but I'm sad that some people just don't think they can change or don't realize what they're doing to themselves at the weight they are.
I know I'm being judgemental when I think like that, but I would never say anything directly to anyone "OMG you're so fat! Lose some weight!" I know intellectually that not everyone will want to lose the weight. I know that change is hard. I know what it is to be fat and the judgement that comes upon someone who doesn't look "normal" to other people and everyone will have someone who thinks poorly of you, no matter what you look like.
I just want to reach out to the people who need my advice, but I need to also be patient and wait for someone to want the help. No one wants unsolicited advice. No one needs to be told what they already know.
I know I'll be there for the people who ask and I won't push anyone who isn't ready and doesn't ask. I'll be there to tell someone they look good when they're getting closer to their goals. The only thing I can do is be someone to listen to the other person, most of the time listening can be the best thing I can do for someone else.
In the end I just need to take the compliment. They're being sincere, no matter what they look like. "Thank you" is what they all want to hear.
Today's Holidays: Gorgeous Grandma Day, National Mosquito Day, National Hot Dog Day and National Vanilla Ice Cream Day.
Share This Post With Others
Report Inappropriate Blog
Member Comments About This Blog Post
Report Inappropriate Comment
My SparkPage
You are absolutely correct...........One has to be ready to begin their journey. Until then, not much of what you say will make any difference.
1039 days ago
Report Inappropriate Comment
My SparkPage
I think you are leading by example.
1040 days ago
Report Inappropriate Comment
My SparkPage
Someone does need to be ready to want to lose weight for them to even begin a journey. When someone says the want to change but, but, but gets in the way---they are not ready.
As for the compliments, be pleased that those who know you notice your doing a good job.
1040 days ago
Report Inappropriate Comment
Until someone is ready and motivated, anything you say will just be taken as criticism. I was the same way. I had to have my own eye opening moment before I was ready and willing to do it. I'm glad I am and I will gladly share my experience with anyone who asks. At first, I wanted to tell everyone but I had to learn for myself.....just say thank you and move on. When they are ready, they will ask.
1040 days ago
Report Inappropriate Comment
My SparkPage
Good for you for using good judgement:)
People will ask when they are ready:)
National Mosquito Day, huh? It's like that every day here!
Hope you have a great one!
1040 days ago
Report Inappropriate Comment
My SparkPage
We can only control ourselves and not the actions of others. They will seek you out when they have their "aha" moment.
1040 days ago
Report Inappropriate Comment
My SparkPage
My mom emailed me today saying that the doctor is concerned about her cholesterol and glucose and made the suggestion that she lose weight. I should not be surprised that the doctor waited for bad numbers to come along before telling her this, when she has been obese for a long time and continues to gain more and more weight every year, when she has chronic back pain and a lot of other complaints.
My mom was upset by his admonition but sounded willing to try. My big concern is that she has always searched for "get thin quick" schemes and spends ridiculous amounts of money on junk. I am very hopeful that she will put in the hard work to make herself healthier and live a long, long time.
I guess I just needed to get that out. :) I think you have a great system -- be judgmental on the inside (who isn't?) but be respectful to the person on the outside. You are very, very correct: No one wants unsolicited advice.
1040 days ago
Report Inappropriate Comment
My SparkPage
We only have the power to enact change within our selves, we can motivate others, inspire others but we cannot do it for them....I appreciate your advice as I am actively enacting change. I too have had a few complements....One person at work blurted out....how ya doing, skinny....that was nice....On sunday during my walk a car full of young guys...slowed down and gave a great wolf call...that boosted my ego a bit...shoot I am 41, I will take it as a compliment when a car full of young men who slow down to cat call at me....that was a nice surpise.....
Overall I would say take the compliment and simply say thank you......
Drat national vanilla ice cream day....doesn't help me with my dillema I posted...Ice cream social at work today....UGH!!!
1040 days ago
Comment edited on: 7/23/2013 1:07:02 PM
Report Inappropriate Comment
My SparkPage
Sometimes, as painful as it is, one must wait to help those who need help. I think you have you the right idea to just accept the compliment and be there for those who wish to know how you did it. Keep at it!
1040 days ago
Add Your Comment to the Blog Post
Log in to post a comment
Disclaimer: Weight loss results will vary from person to person. No individual result should be seen as a typical result of following the SparkPeople program.
Advertisement --
Learn more
about ads on this site.
Get An Email Alert Each Time
CAKEMAKERMOM Posts
See Today's Featured Member Blog Posts
More Blogs by CAKEMAKERMOM
I'm not sure
- 1/28/2016
To make proper decisions
- 1/12/2016
My Food Pusher
- 1/7/2016
Deciding to track for the first week
- 1/6/2016
View All ›
close ×


text:
This topic is archived and can not be replied to any more.
|Canjet To Get 737-500's In The Next Few Months posted Sat Feb 7 2004 16:10:17 by CanadaEH
|WS Likely To Hit YZF In The Next While. posted Mon Jun 26 2006 09:43:03 by Wolsingerjet
|Air India To Add 2 744s In The Next Two Months? posted Thu Aug 7 2003 18:59:44 by Na
|Philippine Airlines In The Next Few Years posted Wed Jan 23 2002 04:42:16 by Ibizajet A330
|If Bermuda II Isn't Lifted In The Next Few Years.. posted Wed Apr 11 2001 17:33:35 by Englandair
|AF Ready To Buy 10% Of AZ In The Next Days posted Thu Mar 7 2002 15:13:33 by Airblue
|Rumour - A380 To Visit GIG And GRU In December posted Thu Aug 3 2006 05:11:00 by Antiuser
|Where Is WN Going In The Next 5 To 10 Years? posted Sun Feb 26 2006 23:51:24 by Nwab787techops
|Will The A380 Be Able To Have Cargo In The Belly posted Tue Nov 23 2004 10:50:42 by Aviationfreak
|WSJ: $10bil In New BCA Orders In The Next Weeks posted Wed Nov 15 2006 06:42:28 by N328KF


text:
Mayor calls for due process, hearing
- Details
- Last Updated on Wednesday, 20 October 2010 00:00
- Published on Wednesday, 20 October 2010 00:00
- Hits: 1088
Council defers action on real estate tax reduction and noise ordinanceThe October Town Council meeting kicked off with competing resolutions about Mayor Fred Rummage's access to town hall. Council member Steve Kennedy placed Resolution 50-10 on the agenda, which is a resolution to reaffirm Resolutions 27-09 and 33-09. Those 2009 resolutions prohibit the mayor from maintaining an office in town hall and further directed the town attorney to issue a "No Trespass" notice to Mayor Rummage.
Rummage, in response to Kennedy's resolution, placed Resolution 51-10 on the agenda, which would rescind Resolutions 27-09 and 33-09. Rummage spoke to the council and citizens present noting that "When I ran for this office there was a physical office for the mayor. It is very embarrassing to me when I have to meet with people from out of town and citizens; this is not an orthodox manner in which to conduct business."
Rummage further said "I was not given legal due process." Rummage believes this issue should be heard first before the council's budget committee. Rummage noted "all the facts were never brought out." Rummage stated that he "wants a public hearing" on his request to rescind the resolutions prohibiting him from having an office at town hall or being present at town hall without an appointment.
Kennedy noted his concerns with maintaining "a stable and secure work environment" for town staff and urged council members to deny the mayor's request. Kennedy further urged council to act upon his resolution.
"Members of council have become concerned and want to act tonight," Kennedy said.
Council member Sparky Ridgely made a motion to table both Kennedy's and Rummage's resolutions and put the issue before the budget committee. Seeber seconded the motion, saying the mayor "deserves due process." Council members Steve Kennedy and Karen Payne cast the only nay votes on Ridgely's motion. The issue of the mayor having an office at town hall will be heard before the budget committee at its November meeting. Four citizens spoke in support of the mayor having an office.
The Town Council also grappled with and deferred action on Resolution 52-10 proposed by member Gary Seeber to reduce the real estate tax rate by $.02 to $.58 per $100. Seeber noted the tax rate should be reduced by $.02 due to recent higher assessments. Facing a Nov. 5 deadline to mail biannual tax bills, council agreed to defer action until town attorney Andrea Erard completes a review of applicable law. Once the review is complete, which should happen in 24-48 hours, council will call a special meeting to consider adoption of Resolution 52-10.
Council also failed to act on Ordinance 590, the new noise ordinance that utilizes maximum decibel levels for both residential and commercial noise and replaces the current pay-to-play permit noise ordinance. Member Karen Payne noted "there are minor language changes" that are still needed in the new ordinance and requested that action be "tabled to the next council meeting."
Also deferred for further review by council was Resolution 47-10, a public hearing on an application for right-of-way abandonment of an undeveloped extension, approximately 280 feet long by 50 feet wide, of Lawrence Lane. The Planning Commission recommended denial of the vacation and sale of the property. Seven citizens spoke at the public hearing with six of them urging council to not abandon the town-owned waterfront property. Two citizens expressed concern with the Planning Commission's findings that were based on the applicant's statement that the request was not initiated by him but by members of council who approached him regarding the acquisition of the property. Member Ridgely was the only nay vote to defer consideration until January saying "We've tabled everything."
Council did, however, unanimously vote to authorize the town manager to make annual parking passes available to out-of-town residents within zip code 22443 (Resolution 46-10). Council also unanimously voted to authorize the town manager to recommend a one-time bonus for town employees (Resolution 48-10). Council also voted to authorize the town manager to enlist the services of small local contractors (Resolution 49-10).
In other matters, School Superintendent Donna Power reported on the replacement of three trailers at the elementary school and requested council to approve vacation of two town-owned rights-of-way to the school board. Power also urged council to take action on a letter sent to council by School Board Chairman Tim Trivett that requested council to match the $50,000 in anticipated funds currently being raised through public support by the school board for a new library.
Westmoreland County Supervisor Larry Roberson reported that funds are available to complete the paving of Santa Maria Avenue. The council passed a Halloween Safety Proclamation for trick or treating to occur 5¬–8 p.m., Sunday, Oct. 31. Edna Edmundson representing the Colonial Beach Historical Society and Museum stated they are looking for homes to be featured on the Christmas home tour.
Kathy Flanagan


text:
January 15, 2010
So, how do you feel about a proposal to legalize Marijuana
Possession in the State of Washington? Wenatchee Bureau Chief Steve Hair posed the question to people outside the
Wenatchee Post Office. A Legislative committee held public hearings yesterday on two bills to either decriminalize
small amounts of pot or legalize its use by adults. On Monday, activists filed a ballot initiative that would
legalize adult marijuana possession, manufacturing and sales.


text:
Children's Health
Milestones for an 18-Month-Old Child - Topic Overview
Social and emotional development
Most children by 18 months of age:
- Do not show much of an interest in playing with other children. But they engage in "parallel play." This is when children play next to or along side each other but don't interact. Adults are their main focus for social growth.
- Are very curious. They like to grab and move almost anything within reach.
- Like to show off for parents and caregivers. They may become happy when they do something they are especially proud of and look to parents for a reaction.
- Like to copy what other people do. For example, your child may like to imitate you and stretch his or her arms up high when you play "so big!" He or she may try to make the same faces you do and copy something you say by jabbering with a similar tone of voice.
Language development
Most children by 18 months of age:
- Understand 10 times more than they are able to put into words.
- Know the names of some people, body parts, and objects. They can often point to an object in a book when asked.
- Use their own language, sometimes called jargon, that is a mix of made-up words and understandable words.
- Follow two-step commands, such as "Go get your teddy bear, and bring it here."
Social and motor development
Most children by 18 months of age:
- Stand from a crawling position without holding onto anything.
- Walk by themselves.
- Hold a cup by themselves.
- Can coordinate hand movement between the fingers and the wrist. This allows your child to eat with a spoon (although at this age, it is guaranteed to be messy).
- Like to press buttons, move handles, and turn knobs.
- Can stack 4 blocks.
WebMD Medical Reference from Healthwise
Last Updated: September 09, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
© 1995-2015 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
1 | 2
1 | 2
Milestones for an 18-Month-Old Child Topics
Today on WebMD
What's that rash?
How healthy is your child's diet?
Treating diarrhea, fever and more.
Understanding your child's changing body.


text:
Notice: All Boston.com forums will be retired as of May 31st, 2016 and will not be archived. Thank you for your participation in this community, and we hope you continue to enjoy other content at Boston.com.
High School baseball
High School baseball
posted at 4/29/2011 4:43 PM EDTTalk about a love fest!! Boston College HS has two of the best pitchers in the state in Donnie Murray and Luke Barkowski, both big, strong righties who throw hard and pound the strike zone. Do you hear about them OF COURS NOT, all you hear about is St Johns Prep, Catholic Memorial and of course Cannaughton, Gorman, Goreham etc etc. These guys are certainly very good obviously and going to D-1 schools, but so are Murray and Barkowski both who have had offers from Ivies, Murray going to Holy Cross and Barkowski prepping at Deerfield to get to Harvard. Do we penalize these guys for being SMART I thought thats what high school sports was all about the student-athlete, give every one a break and stop the lovefest!! BC and Murray beat CM and Gorman and Barkowski beat Wachusett, a western mass power.
Re: High School baseball
posted at 4/29/2011 4:55 PM EDTIs Norm Walsh the worst baseball coach in High School or is it my imagination. All I witness is scared, intimidated kids trying to play a sport they love. Mr. Walsh, I refuse to call him coach, is everything a high school coach shouldn't be. He's a BULLY. Encouraging, proud, helpful, teacher, role model are some of the qualities a coach at the high school or any level for that matter should be, Walsh at BC high is none of these. When are they going to smarten up and dump this dinosaur. Are the Jesuits that desperate that they will continue to look the other way on this matter. For the last three years they have not had an end-of-the-season cookout because both parents and players could not stand to be in the same yard as him, Gods honest truth!! as any player or parent in the last five years. Time to go!! you have ruined too many high school aspirations. Oh by the way with fifteen hundred boys my grandmother could win more state titles!! nough said.
Re: High School baseball
posted at 4/30/2011 11:54 AM EDTwah,wah,wah.stop whining soso,my kid played for coach walsh,and he absolutly helped my son grow into the young man i am so proud of today.it doesnt sound like its about state titles, and cookouts.it sounds like the big mean coach isnt babying your child. .let coach be,he is helping get your child ready for the real world.
Re: High School baseball
posted at 5/1/2011 9:12 AM EDTI don't think BC High is very good this year. Unless the Casey and Regan kids are truly the worst pitchers on their staff. They both got lit up pretty good out here in Central Mass yesterday against SJS (St. John's of Shrewsbury). Last Monday in Westwood SJS outlasted Xaverian in 11 by the score of 2-1. That was a fantastic game between two of the best teams in the state. Wachusett, though a reasonably good Central Mass team, is not an elite program in the class of Xaverian, St. John's Prep, SJS, and BC High. SJ Prep visits SJS on Tuesday which should be a good measuring stick for each team (these two schools played for the D1 basketball title about six weeks ago as well).
I can't comment on the coaching situation at BC High, not cloe enough to the situation.
Re: High School baseball
posted at 5/3/2011 11:04 PM EDTI have to agree after having watched B.C. High's Walsh for a number of years, I'm amazed that parents and players put up with his abusive tirades. I've never seen anything like it in any sport at any level. Not even football line coaches play the mental abuse game the way Walsh does. Penalty says his kid grew from it. He's one of the lucky ones. I find him him more offensive and foul mouthed than Bobby Knight and I'm just dumfounded each year that no one at BC High has grown tired of his antics. It can't be a lot of fun when even in a victory he's lashing out on his players. If I was a parent I'd just video tape any one game and there would be enough evidence of abuse to have him removed from absolutely every program in the state except for one-BC High. With all that said, they are once again a top team loaded with good hitters and a some live arms. Murray and Barkowski are the real deal.
Re: High School baseball
posted at 5/14/2011 2:16 PM EDTWho are the top pitchers this season in EMass baseball?
Re: High School baseball
posted at 5/17/2011 10:30 AM EDTIn Response to Re: High School baseball:Who are the top pitchers this season in EMass baseball?
Posted by powernspeed
North Andover has some talented pitchers this year. Weisman is a lefty and is 4 - 0 and he can bring it. Leavit and Walsh are also 4 - 0. They got a nice team and I would love to see them play against some of the power house big schools. They would probably beat them. You know what they say about pitching.
Re: High School baseball
posted at 5/23/2011 11:24 AM EDTI'm guessing the reason why Shawn McGrath from Everett isnt considered one of the top pitchers in the state may be because he attends a Public School. I watched the young kid pitch Vs. Cannaughton who is a great pitcher. And it clearly seemed to me McGrath out pitched him. The kid was throwing just as fast and his Curve ball was dominate. I heard it was going to be a great pitching match-up and that's what it was. I believe he is attending URI next yr and they are getting a great athlete.
Re: High School baseball
posted at 5/27/2011 12:58 PM EDTIn Response to Re: High School baseball:I'm guessing the reason why Shawn McGrath from Everett isnt considered one of the top pitchers in the state may be because he attends a Public School. I watched the young kid pitch Vs. Cannaughton who is a great pitcher. And it clearly seemed to me McGrath out pitched him. The kid was throwing just as fast and his Curve ball was dominate. I heard it was going to be a great pitching match-up and that's what it was. I believe he is attending URI next yr and they are getting a great athlete.
Posted by jcurt89
Connaughton was 90-92 on the gun and McGrath was 89-91 when they played last Saturday.Both youg men are are real good pitchers and should be successful in college.
Re: High School baseball
posted at 5/31/2011 8:23 PM EDTIn Response to Re: High School baseball:Who are the top pitchers this season in EMass baseball?
Posted by powernspeed
Last year as a sophmore, Braintree's Pat Delano was named a league allstar and led the league in strikeouts with 63. His fastball averaged around 94mph and last year was ranked the 11th best overall player in the class of 2012. In their first tournament game in the 2nd inning against eventual sectional champion Xavrian, he tore his ACL and got tommy john surgery by james andrews in july and should have another dominant senior year next year.Its a shame how you don't hear about this kid, probably becuase he goes to public school. Last i heard he was deciding between Vanderbilt, Purdue, and Stanford
Re: High School baseball
posted at 6/2/2011 1:00 PM EDT
The tournament will test the depth of pitching with the 9 inning format. Everyone has an ace. Some teams have 2. Only a couple have 3 who would be legitimate aces for most schools. Those are the schools to watch.
Aside from pitching there aren't many dominant offensive teams. Look at the leading hitters in Massachusetts. Most are kids playing in D2 or D3, schools like Scituate, Abington, East Bridgewater, Hingham, etc. No disrespect, but these are kids who would be good in D1 but are feasting on inferior competition to post gaudy individual numbers. An some of those leagues use composite or aluminum bats instead of wood - likely to also inflate the numbers.
Teams to watch.
Lexington - Going undefeated in any conference is a huge accomplishment. But will theodds be against them? We'll see.
Walpole - they seem to have won a lot of games by more lopsided scores than most. Can their pitching hold up?
All the Catholic Conference schools. They would all have better records if they weren't busy beating the crap out of eachother. Each one is capable of beating the other on any given day. By far, the most competitive conference in the state.
Lincoln Sudbury - solid all around. So is Franklin.
I haven't seen Everett, Peabody or Braintree this year, but they ususally have solid programs.
Those 12 have a real shot. The brackets will have a lot to do with the end results. For instance, Braintree and Xaverian have a relatively easy road to the South Semifinals, but BC High and CM will have to battle for the right to face the likely winner of Walpole vs. Franklin.
In theNorth, Everett and Lexington have it easy while LS and St. Johns will have duke it out along with Peabody and Xaverian.
Of course, one bad bounce, one missed call, one errantthrow, and all bets are off.
Re: High School baseball
posted at 6/3/2011 12:23 PM EDTre: Boogsie
I agree. Catholic Conference baseball is fun to watch, and Gerry Lambert one baseball coach who loves his job as coach and it's contagious. Go Hawks!
Re: High School baseball
posted at 6/7/2011 4:03 PM EDTThe Globe's converage of H.S Baseball in ALL Div. is pathetic...in this day and age with Tweets, Facebook, Email,.....there should be realtime scores, updates and schedules....ooop sorry meant the NY Times....


text:
WHEELING - Boo Lathon put University on the ropes at the start of the third quarter.
At the end of the period, he provided the final blow.
Lathon, Wheeling Park's sensational senior, registered career highs of 34 points and 20 rebounds to lead the Patriots past the Hawks, 61-55, in a West Virginia Class AAA Region One, Section One boys' basketball semifinal at ''The Palace.''
Article Photos
Wheeling Park's Emil Popicg (1) tries to get around the defense of University's Drew Fraser.
photo by Rick Thorp
The victory secures another trip to Morgantown, where the Patriots (18-5) will face the Mohigans for the sectional crown Friday night. It will be Park's third trip there this season (2-1) and the fourth matchup of the season between the two clubs.
Morgantown topped Brooke, 77-55, in Tuesday night's other sectional semifinal.
''The one thing we couldn't do was physically find a match - whether we were in a zone or man - for Lathon,'' University coach Paul Ingle said.
''He's special player.''
Lathon almost single-handily turned a tight game into a comfortable Park lead in the third quarter.
After the Hawks' Timothy Dixon drained a 3-pointer to cut Park's lead to 31-30, Lathon reeled off seven straight points, including a three-point play. The burst gave the Patriots a 38-30 advantage, their largest lead of the game to that point.
''Boo just continues to have a spectacular year,'' Park coach Michael Jebbia said after watching his squad win its sixth straight. ''We told the guys we wanted him to touch the ball every possession.''
Lathon exploded for 15 of Park's 20 points during the third quarter. He capped the quarter with a long-distance trey from in front of the scorer's table that gave the Patriots a 13-point lead.
The Hawks led just once - 5-4 - but they sure came close to reclaiming it, especially in the second quarter.
Junior Deion Cunningham netted 10 of his team-high 22 points in the second quarter, including eight straight for his team, as the Hawks drew to within 28-25.
University shot well during the quarter, while the Patriots were having trouble getting any offensive consistency.
Turnovers and mental lapses didn't help, either.
''The thing I was upset with was during the final 2 minutes of the quarter we had some turnovers ... we threw the ball away once and lost it another time.
''At halftime, we changed our defenses a little bit. Cunningham's a good player and he got loose on us in the first half. A couple of times down they made us pay and that's a credit to them.''
Of University's 27 first-half points, 23 came in the lane.
Lathon's performance in the third helped Park shoot 8 of 14 from the field during the quarter. Lathon himself was 6 of 7 from the field and 2 of 2 from the free-throw line.
Meanwhile, the Hawks struggled to convert, finishing the quarter 3 of 13 from the floor.
''Basketball is a game of momentum and I thought their coaches did a great job of getting them into something to attack the zone with a little more efficiency,'' Ingle said.
''We found ourselves down, but we fought back.''
The victory was Park's second in six days against University and its first on ''Leap Day'' during Jebbia's tenure.
''The last time we played on 'Leap Day' (2008) we lost in the sectional,'' Jebbia said smiling. ''I have 'Rain Man' characteristics. I can remember dates, stats and things like that. But, it was in the back of my head.''
Now, as the calendar turns in March, the Patriots know they will at least play in the regional.
''We battled and got the win,'' Jebbia said.
Errin Baynes and Luke Saseen each added 10 points for Park.


text:
See All Contributors »
FT. MYERS, Fla. The Iowa State tennis team wrapped up its weekend trip to Florida Sunday morning with a 5-2 loss to Florida Gulf Coast. The Cyclones fall to 1-3 this season, while FGCU improves to 3-1.
Forum Rules
All content owned by CycloneFanatic.com - All rights reserved 2005-09. By viewing this website you agree to the Terms of Service, Site Rules and Legal Disclaimer. The words, views, images and opinions expressed or provided by users do not reflect the opinions or views of CycloneFanatic.com or Iowa State University. The names, words, symbols, and graphics representing Iowa State University are trademarks and copyrights of the University protected by the trademark and copyright laws of the United States of America and other countries and are used on this web site under license from the University. Original site design, premise & construction by Jeremy Lind.


text:
I have never figured this out - why is it I can ride a "comfort bike" with a wide, soft seat, wearing normal shorts and not have big problems (I even did a century once!).
But as soon as I get a road bike, if I don't wear bike shorts, I'll know it either right away or within a few miles?
At first I thought it had to do with the seat, but everyone says a wider, solfter seat will cause MORE problems.
So, I could ask the question this way: Why is a narrow, hard saddle necessary on a road bike to avoid pain, but not on a comfort bike?
The only thing I can think of is the position of the body - leaning forward a lot more on a road style bike.
Recumbent riders can also apparently wear normal shorts, but they aren't leaning forward either.
So, what's the deal on all this?
BTW, I hate having to wear bike shorts, but see no way around it and still have a fast bike (other than a recumbent).


text:
weird salad
So with my mind basically frozen I was at a loss for dinner tonight. Definitely not my style, I like the planning and completion of menus, so I suffer when this happens. Apparently after what feels like a month of indulgences in delicious meals and decadent desserts I have come to the end of that road. Time to get back to real life meals that are more healthy and plannable (is that even a word?).
So anyhoodle I cast about for a while in the kitchen and generally drew a blank on dinner until I spotted some lonely, fresh veggies in the crisper and decided on the weirdest salad ever. Since my husband is in class tonight the kids and I will be on our own for dinner and it feels right to have a salad of forgotten veggies topped with feta and leftover baking pecans. Not that he would object one bit, it's just that with him gone we don't do full blown meals. So I'm off to eat the weirdest salad ever.
1 comment:
Subscribe to: Post Comments (Atom)


text:
In Memoriam: Michael Roan
The Human Rights Center was sorry to learn of the passing on January 4, 2014, of Michael Roan, Executive Director of the Tandem Project and a long-time partner and colleague. Roan was a dedicated public intellectual who advocated for peace and freedom of religion or belief, both locally and internationally. He initiated the Nobel Peace Prize Forum, now in its 26th year, and established the Tandem Project in 1986, a nonprofit focused on freedom of religion or belief.
The Tandem Project and the Human Rights Center collaborated to produce Lifting the Spirit: Human Rights and Freedom of Religion or Belief in 2005, an educational resource designed for use in secondary classrooms, religious institutions, and youth advocacy organizations around the world.
A memorial service for Michael Roan will be held in the Christiansen Center on the Augsburg College campus at 10:00 am, Saturday, March 15, 2014.
To continue Roan's work on freedom of religion or belief, the Human Rights Center is working to organize and post the Tandem Project's archival material to its online Human Rights Library (www.umn.edu/humanrts), one of the world's most widely-used collections of human rights materials. The Center is also raising funds to establish a Michael Roan Fellowship in Freedom of Religion or Belief, which would provide annual support to a Roan Human Rights Fellow to work on projects aimed at upholding the ideals of freedom of religion or belief as established in international human rights law and norms.
Gifts to support either or both efforts can be made to the Human Rights Center online, by going to the Center's website at www.hrcenter.umn.edu and clicking on "Make a Donation" on the upper left-hand sidebar or by sending a check to:
Human Rights Center
University of Minnesota
N120 Mondale Hall
229 19th Ave S.
Minneapolis, MN 55455 USA
Donors should be sure to indicate which project they intend to support.
- Michael Roan, obituary (Star Tribune) - Mar. 2, 2014
- Michael Roan, peace and justice activist (Star Tribune) - Jan. 30, 2014
- Lifting the Spirit: Human Rights and Freedom of Religion or Belief (2005)


text:
Video: U.S.Army Pacific CCP HAST Deploys to Tonga B roll #2
Video by Sgt. 1st Class Kevin Bell
- 486x274 300kbps
- 720x406 800kbps
- 720x406 1500kbps
- 1280x720 3000kbps
- 1280x720 9167kbps
- 1280x720 9170kbps
Soldiers from the U.S. Army Pacific Contingency Command Post, 25th Inf. Div, and the 307 Signal BN deployed to Tonga to take part in "Coral Reef", a humanitarian assistance and disaster relief exercise Sep. 21. CCP Soldiers primarily belong to the Humanitarian Assistance Survey Team who are trained to respond to natural disasters anywhere in the Pacific and can deploy within 24 hours. After a disaster strikes, the HAST conducts assessments on key infrastructure providing the USARPAC Commander with vital information on what the U.S. military can provide to assist the affected nation. Also available in high definition.
This work, U.S.Army Pacific CCP HAST Deploys to Tonga B roll #2, by SFC Kevin Bell, identified by DVIDS, is free of known copyright restrictions under U.S. copyright law.
Date Taken:09.21.2012
Date Posted:09.23.2012 4:16AM
Video ID:156708


text:
I have a complex SQL query which works when I paste it into SQLDeveloper from the source code or the debug logs but fails to return results when using iBATIS 2.3.4. Update: this exact same query also works in mybatis-3.0.6 (with mybatis-spring-1.0.2).
The debug log shows that the query returns no results, but it should return 100+ rows. I know from testing that results map correctly to the domain object. No parameters are mapped, but I intend to add those later.
I encapsulated this in a CDATA block to avoid clashes with <,>,%, and I also tried using the escape characters in the xml. If I replace the nested query named "date_range" with something like
(select 123 start_dt, 134 end_dt from dual) date_range
(which is the logical equivalent) I get the correct number of rows, but the "inventory" column (and therefore the availability column) always returns zero
sum(decode(nvl(o.datetime_id,0),0,0,1)) as inventory
If I replace the nested date_range query with a logically equivalent substr function I receive no rows, either.
select min(datetime_id) start_dt, max(datetime_id) end_dt
from my_dates
where substr(datetime,1,6)='200903'
Does anyone have any idea what the problem might be?
Here's the full query; I've added comments to highlight some things, but these comments are not in the xml:
<select id="reportedObs" resultMap="reportedObsMap">
-- this is the main query from which a few stats are generated
with avail as (
select station_id, start_dt, end_dt, end_dt-start_dt+1 as total_hours
select dates.station_id,
when dates.closed_dt is not null then
when dates.closed_dt>=dates.start_dt then dates.start_dt
when dates.start_dt>dates.por_start_dt then dates.start_dt
when dates.end_dt>dates.por_start_dt then dates.por_start_dt
end as start_dt,
when dates.closed_dt is not null then
when dates.closed_dt>=dates.end_dt then dates.end_dt
when dates.closed_dt>=dates.start_dt then dates.closed_dt
when dates.end_dt>dates.por_start_dt then dates.end_dt
end as end_dt
select sta.station_id, por.por_start_dt, por.por_end_dt, start_dt, end_dt,
when sta.commdate='UN' then null
(select datetime_id
from my_dates
where time=TO_DATE(sta.commdate,'YYYYMMDD')
end as comm_dt,
null as closed_dt
from my_stations sta
join my_special_table por on sta.station_id=por.station_id,
-- There may be some conflict in this nested subquery
-- if replaced with a logically equivalent query, the correct number of rows
-- are returned by the query
select min(datetime_id) start_dt, max(datetime_id) end_dt
from my_dates
where datetime like '200903%'
) date_range
) dates
) all_dates
where start_dt is not null
) -- end of avail query
select avail.station_id,
-- This column always incorrectly returns 0 in the iBATIS results
sum(decode(nvl(o.datetime_id,0),0,0,1)) as inventory,
-- likewise this column, basically using the results above, also incorrectly returns 0
to_char(100*(sum(decode(nvl(o.datetime_id,0),0,0,1))/avail.total_hours),'999D9') as availability
from avail
left outer join my_data o on avail.station_id=o.station_id
and o.datetime_id between avail.start_dt and avail.end_dt
group by avail.station_id, avail.total_hours


text:
this Tuesday @ 9:00 on the travel channel. if you haven't seen the show, it's pretty good. John Ratzenberger (Cliff Clavin) is the host and he tours different factories.
this Tuesday @ 9:00 on the travel channel. if you haven't seen the show, it's pretty good. John Ratzenberger (Cliff Clavin) is the host and he tours different factories.
Thanks for the reminder. I really like the way they do these shows. Makes you want to purchase the products they showcase. I never really wanted Whitmans chocolates before, or a Yankee candle, but after you watch the shows, you suddenly do. I guess I'll be wanting a Trek at about 8:31 PM CST.
Dang it, will have to tape it, have youth group.
Thanks for the info!
A couple years back I saw the one on the Cannondale factory.
Gunnar Sport
Specialized Ruby
Salsa Vaya Ti
Novara Randonee x2
Motobecane Fantom CXX
Jamis Dragon
But not many Trek bikes are still made in America, doesn't that make you wonder how truthful the show - or at least the companies interviewed - are being?
Got lucky and caught the program. I was surprised that Trek let the film crew take pictures of the layup of a carbon frame. Usually, Trek had been pretty secretive about their process. However, the film crew only filmed the carbon process; would have been nice to see their welding process for aluminum and titanium but that may have been in another area.
Yeah. the high end carbon fiber bikes are made in Wisconcin while the lower end and middle end aluminum bikes are made in China. Right? does Trek even make a titanium frame?Originally Posted by chivespa1
My wife works in a LBS and went to their Trek University day here. A surprising number of their bikes are still built in the US. I think in the road category even their middle of the road Al bikes are still made in Waterloo; it is true that their lower end bikes are made in Asia.
Trek makes Lemond which sells a Ti/Carbon bike.
Damn it, I missed it. Does anyone know a place where I can watch it online or download it as a torrent?
And I ride a new 7500, does that mean it was not made here in America?
Don't know. I ride a trek 520 and it has sticker on it - Made in Taiwan. Can't fault it though - It's a great bike.Originally Posted by ReptilesBlade
Me too.... appreciate very much if someone pointing to the place to download the show or watch onlineOriginally Posted by ReptilesBlade
I have Trek T1000 tandem with sticker on the seat tube saying "handbuilt in America". Does it make any difference?
My '01 Lemond says "handbuilt in America" too. I am pretty sure the Lemond 853 frames were welded and painted in the US in '01 so, I guess "handbuilt" means, e.g., "made in the USA with components from Japan" (except that I think it may have Campy dropouts).Originally Posted by nyubie


text:
Images: ISAF senior enlisted leader visits troops in RC-South [Image 1 of 3]
Photo by Sgt. Antony Lee
Sgt. Maj. James E. Booker, senior enlisted leader of International Security Assistance Force, fourth from left, takes a group photo with Command Sgt. Maj. David M. Clark, Regional Command (South) and 4th Infantry Division command sergeant major, left, and other coalition service members. Booker visited Regional Command (South) to meet with Afghan and coalition leaders and receive operational updates. (U.S. Army photo by Sgt. Antony S. Lee)
This work, ISAF senior enlisted leader visits troops in RC-South [Image 1 of 3], by SGT Antony Lee, identified by DVIDS, is free of known copyright restrictions under U.S. copyright law.
Date Taken:05.13.2014
Date Posted:05.14.2014 05:50
Photo ID:1338155
Size:1.96 MB
Location:KANDAHAR AIRFIELD, AF